Jupiter Orphan Therapeutics Inc., of Jupiter, Fla., submitted an IND to the FDA for Jotrol as a treatment for mucopolysaccharidosis type I (MPS I). After a pharmacokinetics trial, Jupiter plans to test Jotrol, a trans-resveratrol product, in patients with Friedreich's ataxia, MPS I and potentially other mitochondrial dysfunction related diseases.